Pembrolizumab with carboplatin and paclitaxel for untreated advanced or recurrent endometrial cancer [ID6381] Draft guidance Technology appraisal guidance 14 April 2025 Natalizumab (originator and ...

To declare any new board interests and executive team interests, and consider any conflicts of interest specific to the meeting. Minutes of the last board meeting (Word) To approve the minutes of the ...

The treatment, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), works by blocking specific hormones that contribute to endometriosis, while also ...

While annual physical checks already take place for people with long-term conditions, we've found that BMI and waist-to-height measurements aren't consistently recorded. Our new approach addresses ...

In final draft guidance published today, we have recommended leniolisib (also called Joenja and made by Pharming) for treating activated phosphoinositide 3-kinase delta syndrome (APDS), an ultra-rare ...

Suggested remit: To appraise the clinical and cost effectiveness of daratumumab with bortezomib, lenalidomide and dexamethasone within its marketing authorisation for untreated multiple myeloma when ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the technology being ...

Our highly specialised technologies (HST) programme is designed specifically to evaluate technologies for ultra-rare, debilitating conditions. It helps encourage research and innovation in areas where ...

A list of downloadable documents created during development.

A list of downloadable documents created during development.